Dexcom (DXCM), the well-known
glucose monitor maker, has been facing significant difficulties with uncharacteristic earnings misses and slow revenue growth, resulting in considerable falls in shares. Major investments firms such as
Oak Ridge Investments LLC and
Allspring Global Investments Holdings LLC have lessened their stakes, while several law firms are encouraging disgruntled investors to contact them regarding potential securities fraud lawsuits. Amidst these challenges, notable figures, such as Jim Cramer, have expressed lost conviction in the company, causing investor scrutiny and backlash. Despite Dexcom's successful growth in the past, it's currently experiencing headwinds and disappointing growth. Furthermore, these issues have led to Dexcom (DXCM) being labelled as one of the worst-performing S&P 500 and NASDAQ stocks in 2024. Nevertheless, Dexcom surpassed Q3 earnings and revenue estimates, though the stock tumbled significantly post-report due to weak growth. Contrarily, the company has strong future prospects, with the launch of first FDA cleared
OTC CGMs and the
G7 CGM system now connecting to Apple watch, demonstrating Dexcom's commitment to innovation.
Dexcom DXCM News Analytics from Mon, 27 May 2024 07:00:00 GMT to Sat, 02 Nov 2024 08:15:43 GMT -
Rating -5
- Innovation 4
- Information 0
- Rumor -3
